Biomarkers may help ID patients at increased risk of neurotoxicity from CD19 CAR T-cell therapyOctober 12, 2017
Bottom Line: New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.
Journal in Which the Study was Published: Cancer Discovery, a journal of the American Association for Cancer Research.
Authors: Cameron J. Turtle, MBBS, PhD, associate member at Fred Hutchinson Cancer Research Center, associate professor at the University of Washington, and attending physician on the Immunotherapy Service at Fred Hutch.
Background: On August 30, 2017, the FDA approved the first CD19 CAR T-cell therapy, tisagenlecleucel (Kymriah), for the treatment of acute lymphoblastic leukemia (ALL) in certain pediatric and young adult patients. Different CD19 CAR T-cell therapies are being developed and tested, and reports show that a small number of patients who received certain forms of this therapy in clinical trials have died from severe neurotoxicity.
Turtle and colleagues sought to provide a detailed clinical, radiological, and pathological characterization of neurotoxicity arising from CD19 CAR T-cell therapy.
How the Study Was Conducted: The researchers used data from a clinical trial in which 133 adult patients with relapsed and/or refractory CD19 B-cell ALL, non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated with lymphodepletion chemotherapy followed by infusion of JCAR014, a type of CD19 CAR T-cell therapy developed at Fred Hutchinson Cancer Research Center.
Within 28 days of treatment, 53 patients (40 percent) developed grade 1 or higher neurologic adverse events and of these 28 (21 percent) had grade 3 or higher neurotoxicity; alterations in neurologic status completely resolved in a majority of cases. Four of the 133 patients (3 percent) developed fatal neurotoxicity.
Results: Turtle and colleagues found that patients with an early onset of CRS were at increased risk of subsequently developing severe neurotoxicity. While tocilizumab (Actemra), an IL-6R antagonist approved by the FDA to treat CRS, was effective in ameliorating CRS-related fever and hypotension in most patients, the team found that its role in preventing or treating neurotoxicity is less clear.
Patients who experienced neurotoxicity were mostly younger and had B-cell ALL, higher tumor burden, and more CD19-positive cells in the bone marrow, compared with those who did not develop this side effect. Data also revealed that those with severe neurotoxicity had endothelial activation, which could contribute to manifestations such as capillary leak, blood coagulation abnormalities, and disruption of the blood-brain barrier that were observed in patients with severe CRS and neurotoxicity.
Turtle and colleagues developed a predictive classification tree algorithm based on the side effects, including fever, and high serum IL-6 and MCP-1, to identify patients, within the first 36 hours after CAR T-cell infusion, who are at increased risk for severe neurotoxicity. Patients at increased risk for this adverse event may benefit from early intervention, Turtle noted; however, he pointed out that additional studies are required.
Authors' Comments: "CD19 CAR T-cell therapy is a highly effective, novel treatment modality that has rapidly expanded in the cancer research and treatment field over the past few years, including recent approval of one form of this therapy by the U.S. Food and Drug Administration [FDA]," said Turtle.
"There is understandably anxiety about some of the side effects of CD19 CAR T-cell therapy, but these treatments have been very effective for a subgroup of patients with resistant disease," he said. "It is important to understand the side effects, such as cytokine release syndrome [CRS] and neurological toxicity."
Enormous improvements have been made in the last few years in strategies to minimize the risk of toxicity, Turtle noted. "Because CAR T-cell therapy is so new, we are still learning how to improve the delivery and reduce the side effects," he added.
Limitations: Limitations of the study include that the characterization of side effects was only from patients who received JCAR014 and not other forms of CD19 CAR T-cell therapies, Turtle said.
Fred Hutch, where Turtle and other co-authors are employed, has a financial interest in Juno, and receives licensing and other payments from the company.
To interview Cameron Turtle, contact Julia Gunther at email@example.com or 215-446-6896.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
American Association for Cancer Research
Related Cancer Research Articles:
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.
CANCER RESEARCH UK has tripled its investment in pancreatic cancer, one of the hardest cancers to treat, since launching its research strategy in 2014 according to new figures published today (Wednesday).
Dr. Hao Zhu, Assistant Professor of Children's Medical Center Research Institute at UT Southwestern, is one of 10 researchers in the nation to receive a Stand Up to Cancer grant to further his studies of a gene whose absence protects mice against liver cancer and promotes liver tissue regeneration in mammals.
Drug-carrying 'nanoghosts' that battle melanoma and new treatments for malignant mesothelioma will be the focus of the first joint research projects led by NYU Langone Medical Center and the Technion-Israel Institute of Technology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
A study by researchers at Marshall University Joan C. Edwards School of Medicine has found that blocking the blood supply of small cell lung cancer tumors may help reduce their growth and delay the regrowth process after treatment.
Related Cancer Research Reading:
The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)
Winner of the Pulitzer Prize, and now a documentary from Ken Burns on PBS, The Emperor of All Maladies is a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence.
Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly... View Details
The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable--and How We Can Get There
by Vincent T. DeVita Jr. M.D. (Author), Elizabeth DeVita-Raeburn (Author)
The true story of the war on cancer from one of its generals
Cancer touches everybody's life in one way or another. But most of us know very little about how the disease works, why we treat it the way we do, and the personalities whose dedication got us where we are today. For fifty years, Dr. Vincent T. DeVita Jr. has been one of those key players: He has held just about every major position in the field, and he developed the first successful chemotherapy treatment for Hodgkin's lymphoma. As one of oncology's leading figures, DeVita knows what cancer looks like from the lab... View Details
Cancer Research Secrets: Therapies which work and those which don't
by Keith Scott-Mumby (Author), Dragos Balasoiu (Designer)
A comprehensive report on a wide range of cancer alternative treatments that have been shown to work. These are not always alternatives to orthodox treatments but can run in parallel. The author is an internationally-known MD with knowledge and experience of a wide range of holistic therapies. View Details
Breast Cancer Smoothies: 100 Delicious, Research-Based Recipes for Prevention and Recovery
by Daniella Chace (Author)
The statistics are staggering. Breast cancer is the most common type of cancer among women--About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime. Second only to heart disease by a mere one percent, every ounce of prevention and every window of opportunity for healing is critical. In order to reduce the risk of developing this common disease, you need a targeted plan to protect yourself from common breast toxins and to strengthen your immune defenses.
In her delightful new book, Daniella breaks down the complex topic of... View Details
WHO Classification of Tumours of the Female Reproductive Organs (IARC WHO Classification of Tumours)
by International Agency for Research on Cancer (Author)
WHO Classification of Tumours of Female Reproductive Organs is the sixth volume in the Fourth Edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.
Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms... View Details
A Quick Guide to Cancer Epidemiology (SpringerBriefs in Cancer Research)
by Paolo Boffetta (Author), Stefania Boccia (Author), Carlo La Vecchia (Author)
A Quick Guide to Cancer Epidemiology is an ideal addition to Springer Briefs in Cancer Research. The Brief provides core concepts in cancer epidemiology and also gives a snapshot of the epidemiology of seventeen human cancers. The Brief aims to provide-with quantitative focus-estimates of the global burden of neoplasms, of recent and likely future trends, distribution, causes and strategies for prevention for major groups of cancers. Finally, the Brief will give an overview of severals factors that cause cancer including dietary factors, tobacco smoking, obesity and alcohol... View Details
The Cancer Chronicles: Unlocking Medicine's Deepest Mystery
by George Johnson (Author)
A New York Times Notable Book of 2013
When the woman he loved was diagnosed with a metastatic cancer, George Johnson set out to learn everything he could about the disease and the people who spend their careers trying to understand and to fight it. What he discovered is a revolution under way—an explosion of new ideas about what cancer really is and where it comes from.
Deftly excavating and illuminating decades of investigation and analysis, rooted in every discipline from evolutionary biology to game theory and physics, Johnson explores what we know—and... View Details
The Awful Truth About Chemotherapy and Radiation
by Cancer Research International (Author), Cancer Research International (Editor), Cancer Research International (Editor)
The Awful Truth About Chemotherapy and Radiation by Cancer Research International reveals the truth about chemotherapy and radiation. It represents 114 pages of power packed facts and common sense. Quote from the introduction: He who asks is a fool for five minutes, but he who does not ask remains a fool forever. This referenced book includes: Part I: Why Chemotherapy Does Not Work 97.9% of the Time; Part II: The Cancer Establishment (How It All Started); Part III: Cancer is an Industry; Part IV: Understanding Conventional Cancer Treatment; and Part V: How Conventional Treatments Have Failed.... View Details
WHO Classification of Tumours of the Central Nervous System (IARC WHO Classification of Tumours)
by International Agency for Research on Cancer (Author)
WHO Classification of Tumours of the Central Nervous System is the revised fourth edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.
Diagnostic criteria, pathological features, and associated genetic alterations are described in a disease-oriented manner. Sections on all recognized neoplasms and their variants... View Details
Metabolism in Cancer (Recent Results in Cancer Research)
by Thorsten Cramer (Editor), Clemens A. Schmitt (Editor)
This textbook presents concise chapters written by internationally respected experts on various important aspects of cancer-associated metabolism, offering a comprehensive overview of the central features of this exciting research field. The discovery that tumor cells display characteristic alterations of metabolic pathways has significantly changed our understanding of cancer: while the first description of tumor-specific changes in cellular energetics was published more than 90 years ago, the causal significance of this observation for the pathogenesis of cancer was only discovered in the... View Details